Glenmark Pharma shares soar 8% on FDA clean report, Investec predicts 17% upside

The global brokerage firm said that it expects both earnings momentum and importantly cash flow generation to continue. Additionally, it sees Glenmark as more of an India / RoW play as these two contribute >70% of its EBITDA.